Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 72 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Portosystemic Encephalopathy Clear all
Completed Not applicable Interventional

Tackling 30-day Readmissions in Patients With Cirrhosis: The SALTYFOOD Trial

NCT03493204
View directory record Official record
Conditions
Hepatic Encephalopathy, Ascites, Liver Diseases, Cirrhosis
Interventions
Meal delivery, Standard pamphlet with Dietary Advice
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Phase 2Phase 3 Interventional Results available

13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF

NCT02786836
View directory record Official record
Conditions
Acute Liver Failure
Interventions
13C-Methacetin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Phase 1Phase 2 Interventional Results available

FMT in Cirrhosis and Hepatic Encephalopathy

NCT03796598
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
Fecal Microbial transplant Capsules, Fecal Microbial Transplant Enema, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Phase 1 Interventional

Fecal Transplant in Recurrent Hepatic Encephalopathy

NCT02636647
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis
Interventions
Fecal transplant
Biological
Lead sponsor
Jasmohan Bajaj
Federal
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 20, 2026, 11:28 PM EDT
Terminated Phase 2 Interventional

Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy

NCT04155099
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Liver
Interventions
RBX7455, Placebo
Biological
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Jefferson, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Not applicable Interventional

iPod Games in Hepatic Encephalopathy

NCT02154282
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis
Interventions
ipod games
Behavioral
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Not applicable Interventional

Effect of Yogurt on Minimal Hepatic Encephalopathy

NCT00312078
View directory record Official record
Conditions
Cirrhosis, Minimal Hepatic Encephalopathy
Interventions
Yogurt Supplementation
Dietary Supplement
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
24 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 1, 2007 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy

NCT00686920
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
31
States / cities
Birmingham, Alabama • Aurora, California • Fresno, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 20, 2026, 11:28 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

RENEW: Study of Porcine Liver Support in Participants With Acute-on-Chronic Liver Failure

NCT07429838
View directory record Official record
Conditions
Acute on Chronic Liver Failure (ACLF), Hepatic Encephalopathy (HE)
Interventions
metra® Extracorporeal Liver Cross-Circulation (ELC) system (OrganOx), EGEN-5784 (genetically engineered porcine liver)
Device · Biological
Lead sponsor
eGenesis, INC
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
St Louis, Missouri • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Phase 2 Interventional

AST-120 Used to Treat Mild Hepatic Encephalopathy

NCT00867698
View directory record Official record
Conditions
Mild Hepatic Encephalopathy
Interventions
AST-120
Drug
Lead sponsor
Ocera Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Not applicable Interventional

Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents

NCT04315571
View directory record Official record
Conditions
Hypertension, Portal, Ascites
Interventions
Gore® Viatorr® Endoprosthesis with controlled expansion, Large Volume Paracentesis with albumin infusion
Device · Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Phase 1 Interventional

Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy

NCT00992290
View directory record Official record
Conditions
Minimal Hepatic Encephalopathy
Interventions
Lactobacillus GG, Placebo
Biological
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Phase 2 Interventional Results available

VE303 for Treatment of Hepatic Encephalopathy (HE)

NCT04899115
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
Placebo, VE303, oral vancomycin
Drug
Lead sponsor
Patricia Bloom
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 20, 2026, 11:28 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

NCT05297448
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin SSD, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
90
States / cities
Homewood, Alabama • Chandler, Arizona • Sun City, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 20, 2026, 11:28 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS

NCT02048969
View directory record Official record
Conditions
Hepatic Encephalopathy, Liver Cirrhosis
Interventions
Flumazenil, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 20, 2026, 11:28 PM EDT
Terminated Not applicable Interventional

The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.

NCT01846806
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Oct 20, 2026, 11:28 PM EDT
Not yet recruiting Not applicable Interventional

Endoscopic Shunts Embolization for Refractory Hepatic Encephalopathy

NCT07553858
View directory record Official record
Conditions
Hepatic Encephalopathy, Liver Cirrhosis, Portal Shunt Systemic
Interventions
Endoscopic ultrasound-guided transgastric embolization of the spontaneous portosystemic shunts, Interventional Radiology for shunt embolization/retrograde tranvenous obliteration
Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 20, 2026, 11:28 PM EDT
Terminated Phase 4 Interventional Results available

Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

NCT01846663
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Placebo, Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 20, 2026, 11:28 PM EDT
Active, not recruiting Phase 2 Interventional

Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy

NCT03420482
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Fecal Microbiota Transplant (FMT) oral capsules, Placebo oral capsule
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 20, 2026, 11:28 PM EDT
Withdrawn No phase listed Observational

The Effect of a Large-volume Paracentesis on Fatigue, Sleep, and Quality of Life in Cirrhosis

NCT01777971
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy, Ascites, Fatigue
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Oct 20, 2026, 11:28 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Eye Movement Testing for Diagnosing Encephalopathy in Patients With Liver Disease

NCT04940416
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
Neurofit (oculometric testing)
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 20, 2026, 11:28 PM EDT
Active, not recruiting Phase 2 Interventional

TReatment for ImmUne Mediated PathopHysiology

NCT04862221
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions
High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Year to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 20, 2026, 11:28 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy

NCT00597909
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
sodium phenylacetate and sodium benzoate injection 10% / 10%, placebo solution (10% dextrose)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Fresno, California • Loma Linda, California • Odessa, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 20, 2026, 11:28 PM EDT
Terminated Phase 4 Interventional

Quality of Life and Nutritional Improvements in Cirrhotic Patients

NCT01842113
View directory record Official record
Conditions
Liver Cirrhosis, Hepatic Encephalopathy, Portal Hypertension
Interventions
Rifaximin, Lactulose, Lactulose Placebo, Rifaximin Placebo
Drug
Lead sponsor
Tampa General Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Oct 20, 2026, 11:28 PM EDT